Malignancies: Clinical Trials

7 trials for Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7

Follow Malignancies: new trials by email Literature Review of Malignancies trials Research Report on Malignancies

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
chemotherapy, venetoclax - Malignancies, Acute Lymphoblastic Leukemia (ALL)
Phase 1CompletedAbbVie1432017-11-082023-05-22
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
REGN3767, cemiplimab - Malignancies
Phase 1CompletedRegeneron Pharmaceuticals3332016-11-072026-11-19
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
PWT-143 - Malignancies
Phase 1CompletedMEI Pharma, Inc.352015-06-292017-08-29
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Carfilzomib, Dexamethasone - Neoplasms, Malignancies
Phase 1CompletedEmory University222014-08-012017-02-07
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
PWT33597 mesylate - Malignancies
Phase 1CompletedPathway Therapeutics, Inc.222011-06-012012-10-25
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
Aroplatin - Malignancies, B-Cell Lymphoma
Phase 1CompletedAgenus Inc.212006-03-012008-10-27
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
CS-1008 (humanized anti-DR5 antibody) - Malignancies, Lymphoma
Phase 1CompletedDaiichi Sankyo402007-09-11

Narrower conditions

Neoplasms (7)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neuroblastoma (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphatic Diseases (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms by Histologic Type (3)  ·  Lymphoma (2)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Myeloid (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neoplasms, Glandular and Epithelial (1)

Interventions

Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Drug Therapy (1)  ·  bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II) (1)  ·  carfilzomib (1)  ·  cemiplimab (1)  ·  tigatuzumab (1)  ·  venetoclax (1)

Sponsors

AbbVie (1)  ·  Agenus Inc. (1)  ·  Daiichi Sankyo (1)  ·  Emory University (1)  ·  MEI Pharma, Inc. (1)  ·  Pathway Therapeutics, Inc. (1)  ·  Regeneron Pharmaceuticals (1)

Countries

United States (6)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Switzerland (1)

Top investigators

Bradley C. Carthon, MD, PhD (1)  ·  Pui Leung, MBChB (1)

Results publications

PMID 29595064, PMID 30458930, PMID 34088831, PMID 38900987, PMID 39368878, PMID 39422598, PMID 40062648, PMID 40266036

NIH funding

2017 (1)